

Psoriasis Prime Time 2

TYK Inhibition in Hard-to-Treat Psoriasis

References

- Alwan W, Nestle FO. Pathogenesis and treatment of psoriasis: exploiting pathophysiological pathways for precision medicine. *Clin Exp Rheumatol*. 2015;33(5 Suppl 93):S2-S6.
- Armstrong AW, Read C. Pathophysiology, clinical presentation, and treatment of psoriasis: A review. *JAMA*. 2020;323(19):1945-1960.
- Armstrong AW, Lebwohl M, Warren, RB, et al. Deucravacitinib in plaque psoriasis: 3-year safety and efficacy results from the phase 3 POETYK PSO-1 and PSO-2 trials. *SKIN J Cutan Med*. 2023;7(6):s240.
- Armstrong A, Lynde C, Forman S et al. Efficacy and safety results from the randomized, double-blind, placebo-controlled phase 2b trial of the oral TYK2 inhibitor TAK-279 in moderate-to-severe psoriasis Presented at: EADV Congress; 10/11/23-10/14/23; Berlin, Germany. Abst 2505.
- Armstrong AW, Lebwohl M, Warren RB, et al. Deucravacitinib in plaque psoriasis: 4-year safety and efficacy results from the phase 3 POETYK PSO-1, PSO-2, and LTE trials. Presented at: European Academy of Dermatology & Venereology Symposium; 5/17/24; St. Julian's, Malta.
- Baker KF, Isaacs JD. Novel therapies for immune-mediated inflammatory diseases: What can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn's disease and ulcerative colitis?. *Ann Rheum Dis*. 2018;77(2):175-187.
- Blauvelt A, Rich P, Sofen H, et al. Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in scalp, nail, and palmoplantar psoriasis: subgroup analyses of the phase 3 POETYK PSO-1 and PSO-2 trials. Presented at: Fall Clinical Dermatology Conference for NPs and PAs; 6/3/22-6/5/22; Scottsdale, AZ.
- Choy EH. Clinical significance of Janus Kinase inhibitor selectivity [published correction appears in *Rheumatology (Oxford)*. 2019 Jun 1;58(6):1122]. *Rheumatology (Oxford)*. 2019;58(6):953-962.
- Drakos A, Torres T, Vender R. Emerging oral therapies for the treatment of psoriasis: A review of pipeline agents. *Pharmaceutics*. 2024;16(1):111.
- Dudakov JA, Hanash AM, van den Brink MR. Interleukin-22: Immunobiology and pathology. *Annu Rev Immunol*. 2015;33:747-85.
- Green A, Shaddick G, Charlton R, et al. Modifiable risk factors and the development of psoriatic arthritis in people with psoriasis. *Br J Dermatol*. 2020;182(3):714-720.
- Joven-Ibáñez B, Rivera R, Hernandez G, et al. OP0010 Evaluation of the risk of psoriatic arthritis in patients with psoriasis undergoing biological treatment. Global population study (TRINETX). *Ann Rheum Dis*. 2024;83:168-169.
- Kivitz A, Muensterman ET, Kavanaugh A, et al. Efficacy and safety outcomes of tak-279, a selective oral tyrosine kinase 2 (tyk2) inhibitor, from a randomized, double-blind, placebo-controlled phase 2b trial in patients with active psoriatic arthritis. *Ann Rheum Dis*. 2024; 83:149-151.

- Lebwohl M, Warren RB, Sofen H, et al. Deucravacitinib in plaque psoriasis: 2-year safety and efficacy results from the phase III POETYK trials. *Br J Dermatol*. 2024;190(5):668-679.
 - Mease PJ, Palmer JB, Hur P, et al. Utilization of the validated Psoriasis Epidemiology Screening Tool to identify signs and symptoms of psoriatic arthritis among those with psoriasis: a cross-sectional analysis from the US-based Corrona Psoriasis Registry. *J Eur Acad Dermatol Venereol*. 2019;33(5):886-892.
 - Mease PJ, Deodhar AA, van der Heijde D, et al. Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis. *Ann Rheum Dis*. 2022;81(6):815-822.
 - Merola J, Mease P, Armstrong A, et al. Deucravacitinib, an oral, allosteric, selective tyrosine kinase 2 inhibitor, in patients with plaque psoriasis who screened positive for psoriatic arthritis in POETYK PSO-1 and POETYK PSO-2: Effect on joint pain and peripheral joint disease vs placebo and apremilast [abstract]. *Arthritis Rheumatol*. 2023; 75 (suppl 9)
 - Morand E, Merola JF, Tanaka Y, Gladman D, Fleischmann R. TYK2: an emerging therapeutic target in rheumatic disease. *Nat Rev Rheumatol*. 2024;20(4):232-240.
 - Ogdie A, Gelfand JM. Clinical risk factors for the development of psoriatic arthritis among patients with psoriasis: A review of available evidence. *Curr Rheumatol Rep*. 2015;17(10):64.
 - Ogdie A, Harrison RW, McLean RR, et al. Prospective cohort study of psoriatic arthritis risk in patients with psoriasis in a real-world psoriasis registry. *J Am Acad Dermatol*. 2022;87(6):1303-1311.
 - Schwartz DM, Bonelli M, Gadina M, O'Shea JJ. Type I/II cytokines, JAKs, and new strategies for treating autoimmune diseases. *Nat Rev Rheumatol*. 2016;12(1):25-36.
 - Spencer RK, Jin JQ, Elhage KG, et al. Comparative efficacy of biologics and oral agents in palmoplantar psoriasis and palmoplantar pustulosis: A systematic review and network meta-analysis of randomized clinical trials. *J Am Acad Dermatol*. 2023;89(2):423-425.
 - Wroblewski ST, Moslin R, Lin S, et al. Highly selective inhibition of tyrosine kinase 2 (TYK2) for the treatment of autoimmune diseases: Discovery of the allosteric inhibitor BMS-986165. *J Med Chem*. 2019;62(20):8973-8995.
-